Catalyst
Slingshot members are tracking this event:
Phase 3 VITAL study results for NEOD001 in newly diagnosed patients with AL Amyloidosis in cardiac dysfunction. - Discontinued
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
PRTA |
|
|
Additional Information
Study is 9 months long from clinical trials.gov
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 23, 2018
Occurred Source:
http://ir.prothena.com/releasedetail.cfm?ReleaseID=1064584
Related Projects
- What can we expect from the upcoming data releases of Prothena’s Phase 3 VITAL and Phase 2b PRONTO Amyloidosis Studies? PRTA, TKPYY Executed On: Sep 13, 2017 at 10:30 AM EDT
Related Keywords
Neod001, Vital Study, Al Amyloidosis, Nt-probmp, Discontinued